Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China

BACKGROUND: Currently, no second-line systemic treatment regimen has been recommended in advanced biliary tract cancer (BTC). Cumulative clinical evidence showed that systemic treatment with tyrosine kinase inhibitors (TKIs) in combination with immunotherapy may shed light on the dim clinical outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Changying, Li, Yulong, Yang, Cheng, Qiao, Liang, Tang, Liukang, Zheng, Yuting, Chen, Xue, Qian, Youwen, Yang, Jiamei, Wu, Dong, Xie, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364266/
https://www.ncbi.nlm.nih.gov/pubmed/35967452
http://dx.doi.org/10.3389/fimmu.2022.946861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364266/
https://www.ncbi.nlm.nih.gov/pubmed/35967452
http://dx.doi.org/10.3389/fimmu.2022.946861

Ejemplares similares